These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

721 related items for PubMed ID: 26247170

  • 41. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C, Büttner-Herold M, Bertz S, Schiffer M, Buchholz B.
    BMC Nephrol; 2020 Mar 24; 21(1):104. PubMed ID: 32204691
    [Abstract] [Full Text] [Related]

  • 42. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
    Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M.
    Am J Kidney Dis; 2014 Oct 24; 64(4):633-7. PubMed ID: 24656451
    [Abstract] [Full Text] [Related]

  • 43. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.
    van den Brand JA, Verhave JC, Adang EM, Wetzels JF.
    Nephrol Dial Transplant; 2017 Jan 01; 32(suppl_1):i115-i122. PubMed ID: 28391343
    [Abstract] [Full Text] [Related]

  • 44. Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab.
    Okuda Y, Ishikura K, Terano C, Harada R, Hamada R, Hataya H, Ogata K, Honda M.
    Nephrology (Carlton); 2016 Mar 01; 21(3):261-5. PubMed ID: 26818219
    [Abstract] [Full Text] [Related]

  • 45. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T, Okumi M, Unagami K, Kanzawa T, Sawada A, Kawanishi K, Omoto K, Ishida H, Tanabe K.
    Nephrology (Carlton); 2016 Jul 01; 21 Suppl 1():35-40. PubMed ID: 26970541
    [Abstract] [Full Text] [Related]

  • 46. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
    Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provôt F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Châtelet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Frémeaux-Bacchi V.
    Blood; 2021 May 06; 137(18):2438-2449. PubMed ID: 33270832
    [Abstract] [Full Text] [Related]

  • 47. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.
    Nefrologia; 2015 May 06; 35(5):421-47. PubMed ID: 26456110
    [Abstract] [Full Text] [Related]

  • 48. Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation.
    Krishnan AR, Siva B, Chakera A, Wong G, Wong D, Lim WH.
    Nephrology (Carlton); 2017 Feb 06; 22 Suppl 1():28-31. PubMed ID: 28176477
    [Abstract] [Full Text] [Related]

  • 49. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
    Cao M, Leite BN, Ferreiro T, Calvo M, Fernández C, Alonso Á, Rodriguez A, Salvador P, Seijo R, Pita S, Arjona E, Rodríguez de Córdoba S, Valdés Cañedo F.
    Am J Nephrol; 2018 Feb 06; 48(3):225-233. PubMed ID: 30205388
    [Abstract] [Full Text] [Related]

  • 50. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
    Gäckler A, Schönermarck U, Dobronravov V, La Manna G, Denker A, Liu P, Vinogradova M, Yoon SS, Praga M.
    BMC Nephrol; 2021 Jan 06; 22(1):5. PubMed ID: 33407224
    [Abstract] [Full Text] [Related]

  • 51. Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis.
    Kozlovskaya NL, Korotchaeva YV, Bobrova LA.
    J Matern Fetal Neonatal Med; 2019 Sep 06; 32(17):2853-2859. PubMed ID: 29606012
    [Abstract] [Full Text] [Related]

  • 52. Eculizumab in paediatric atypical haemolytic uraemic syndrome: Lessons learned from a single-centre experience in the United Arab Emirates.
    Kumar G, Al-Masri O, Alismaili Z, Tawfik E, Al-Ghabra MK, Ilyas SH, Al-Khasawneh E.
    J Paediatr Child Health; 2019 Oct 06; 55(10):1237-1240. PubMed ID: 30714243
    [Abstract] [Full Text] [Related]

  • 53. Renal Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Single Center Experience.
    Alpay N, Ozçelik U.
    Transplant Proc; 2019 Sep 06; 51(7):2295-2297. PubMed ID: 31400975
    [Abstract] [Full Text] [Related]

  • 54. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M.
    Clin Exp Immunol; 2017 Feb 06; 187(2):304-315. PubMed ID: 27784126
    [Abstract] [Full Text] [Related]

  • 55. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
    Wright RD, Bannerman F, Beresford MW, Oni L.
    BMC Nephrol; 2020 Jun 30; 21(1):245. PubMed ID: 32605540
    [Abstract] [Full Text] [Related]

  • 56. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
    Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H.
    J Nephrol; 2017 Feb 30; 30(1):127-134. PubMed ID: 26995002
    [Abstract] [Full Text] [Related]

  • 57. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F, Frémeaux-Bacchi V, Loirat C.
    Eur J Intern Med; 2013 Sep 30; 24(6):492-5. PubMed ID: 23756030
    [Abstract] [Full Text] [Related]

  • 58. Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome.
    Ryan M, Donato BMK, Irish W, Gasteyger C, L'Italien G, Laurence J.
    Pharmacoeconomics; 2020 Mar 30; 38(3):307-313. PubMed ID: 31828738
    [Abstract] [Full Text] [Related]

  • 59. Ravulizumab facilitates reduced burden of vascular access, a major benefit in paediatric atypical haemolytic uraemic syndrome.
    Bleathman F, Kausman JY, Hosking LM, Forbes TA.
    J Paediatr Child Health; 2024 Jun 30; 60(6):183-187. PubMed ID: 38661088
    [Abstract] [Full Text] [Related]

  • 60. Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement.
    Hu H, Nagra A, Haq MR, Gilbert RD.
    Pediatr Nephrol; 2014 Jun 30; 29(6):1103-6. PubMed ID: 24317637
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.